soul study semaglutide SOUL: Oral Bests Usual Care in High-Risk Type 2 Diabetes SOUL trial: Oral semaglutide demonstrates
Pay in 4 interest-free payments of $7.31 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Live Spec
SOUL trial: Oral semaglutide demonstrates a 14% reduction in risk of major adverse CV events Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo Kidney International Oral Semaglutide Gets FDA Approval for CV Event Reduction in High risk Diabetes Patients Two year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial Nature Medicine European Everything you want to know about the SOUL Trial: Effects of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk. Join Prof. SOUL Trial (NEJM 2025): Oral semaglutide led to a 14% in major CV events vs placebo in T2DM with ASCVD or CKD no in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine
Store: skntheory.com · Domain: skntheory.com
